$RAFA Rafarma has Registered NOYA THERAPEUTICS company in Israel RAFA continues to develop business, expand, strengthen its position in the Israeli market Israeli Corporations Authority (ICA) registered NOYA THERAPEUTICS LTD co noyarp.com/news

$RAFA Israel has a strong position in the pharmaceutical industry & an excellent reputation in the biomedicine market Rafarma Pharmaceuticals sees large-scale prospects for its growth in the country & opportunities for the implementation of the projects local.infobel.co.il/IL101234311/no…

$RAFA Rafarma will participate in a conference dedicated to modern Neuroscience noyarp.com/news Ilya Shpurov Chairman #RAFA is the Conference organizing committee member Landmark event for leading Scientific Centers & Universities 200 Universities will participate

$RAFA Rafarma Pharmaceuticals negotiated with the Ministry of Kazakhstan noyarp.com/news

$RAFA Q1 2023 Financial Results otcmarkets.com/stock/RAFA/dis…

$RAFA 2023 - Q1 Financial Highlights $87.3 Million in Assets $10.1 Million in Revenues $15.1 Million Cash Shares Outstanding - Unchanged 87.7 Million Latest News - noyarp.com/news

$RAFA Rafarma Pharmaceuticals meets to discuss partnership with Korean CEO Jae Min Son from CERES F&D Inc. noyarp.com/news CERES is a Biopharmaceutical Co with cGMP-certified production facilities that produces high quality, effective medicines ceresfnd.com

$RAFA - Rafarma Pharmaceuticals is negotiating with an Investment Fund noyarp.com/news Rafarma Pharmaceuticals, Inc. (OTC: RAFA) Chairman of the Board Ilya Shpurov met with the representatives of the investment fund located in Hangzhou City, China.

$RAFA - Rafarma continues to develop projects on isotopes in Kazakhstan. Negotiations with The Institute of Nuclear Physics of the Ministry of Energy of the Republic of #Kazakhstan noyarp.com/news Parties continue to discuss cooperation and evaluate production volumes

Updated $RAFA Filing 07/06/23 at OTC Markets otcmarkets.com/otcapi/company…

$RAFA Recent Activity ... Opening enterprise HONG KONG - CHINA Developing Projects in KAZAKHSTAN Negotiating with an Investment Fund - CHINA Meeting with CERES F&D - KOREA Expansion of production - ISRAEL Agreement with Istem Medikal - TURKEY Tashkent Pharma Park - UZBEKISTAN

$RAFA Q2 2023 Combined Financial statements otcmarkets.com/otcapi/company… Revenues $21 million Assets $80 million Cash $14 million Income $2.3 million Shares outstanding - unchanged

$RAFA News Release finance.yahoo.com/news/rafarma-p…

$RAFA - Rapharma and Kelun Lifesciences have entered into a preliminary agreement noyarp.com/post/rapharma-…

$RAFA - Rafarma Pharmaceuticals Signed a Preliminary Agreement for Radiopharmaceutical Production Center noyarp.com/post/rafarma-p…

$RAFA News Rafarma has entered into a preliminary agreement with Kelun Lifesciences (Pvt) Ltd, a Pharmaceutical Company based in Sri Lanka newsfile.refinitiv.com/getnewsfile/v1…

$RAFA Call with Management 12 Noon EST Dec 18th Join Zoom Meeting us06web.zoom.us/j/86294829794?… Meeting ID: 862 9482 9794 Passcode: 564976